Related Experiment Video
Updated: Apr 15, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Interferon gamma polymorphisms and hepatitis B virus-related liver cirrhosis risk in a Chinese population
1Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, 530021 Guangxi People's Republic of China.
Background:
Previous studies proved that interferon gamma (IFN-γ) gene polymorphisms were associated with the risk of hepatitis B virus (HBV) infection. However, the association between IFN-γ polymorphisms and HBV-related liver cirrhosis (HBV-LC) risk is still unclear.
Methods:
IFN-γ +874 T/A and +2109G/A genotypes were determined in 126 HBV-LC patients, 129 chronic hepatitis B(CHB) patients, and 173 early HBV infection controls using a sequence-specific primer-polymerase chain reaction and a polymerase chain reaction-restriction fragment length polymorphism, respectively.
Results:
Significant associations were observed between +2109A/G polymorphisms and HBV-LC risk in the co-dominant model (GG vs. AA: OR = 0.321, 95% CI = 0.130-0.793, P = 0.014), the allelic model (OR = 0.565, 95% CI = 0.388-0.825, P = 0.003), the dominant model (OR = 0.551, 95% CI = 0.344-0.883, P = 0.013), and the recessive model (OR = 0.385, 95% CI = 0.159-0.930, P = 0.034). In addition, haplotype analysis indicated that the T(+874)G(+2109) haplotype significantly decreased the HBV-LC risk (OR = 0.106, 95% CI = 0.022-0.502, P = 0.000), and A(+874)A(+2109) haplotype significantly increased the LC risk (OR = 1.485, 95% CI = 1.065-2.070, P = 0.019). No significant associations were observed between IFN-γ +874 T/A polymorphisms and HBV-LC risk, as well as the two single-nucleotide polymorphisms (SNPs) and CHB risk (P > 0.05).
Conclusions:
Our observations suggested a significant association of IFN-γ polymorphisms with HBV-LC risk in the Chinese population.
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

